Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 29Etoposide 15Daunorubicin 13tipifarnib 10Mitoxantrone 10Idarubicin 8alvocidib 6Azacitidine 6Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Busulfan 5valspodar 4Bortezomib 4fludarabine phosphate 3aldesleukin 3Vorinostat 3Tretinoin 3Sorafenib 3Radiotherapy 3Gemtuzumab 3Cyclophosphamide 3tanespimycin 2sargramostim 2lintuzumab 2laromustine 2entinostat 2Watchful Waiting 2Topotecan 2Thioguanine 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Monocytic, Acute × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡